BioSpace News Archive

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today outlined its strategic priorities for 2023.

Inari Medical, Inc. today announced preliminary unaudited fourth quarter and full year 2022 revenue and provided estimates for its 2023 guidance.

Rivermark MedicalTM, a company dedicated to developing first-line device therapy for benign prostatic hyperplasia (BPH), announced today the successful first-in-human (FIH) use of its FloStentTM System as part of the Company’s RAPID-1 FIH clinical study.

OrganOx Ltd (“OrganOx” or the “Company”), a world-leading medical technology company committed to making every donated organ count with metra®, a fully automated normothermic machine perfusion (NMP) device for liver transplantation, today announces the successful recruitment of the first patient into its Post Approval Study (PAS).

EpiVax, Inc. (“EpiVax”) and Zoetis, are pleased to announce an exclusive collaboration to develop CircoMatch™, a unique bioinformatics tool that predicts the coverage of Porcine Circovirus Type 2 (PCV2) vaccines against field isolates of PCV2.

Neurotech Pharmaceuticals, Inc., a clinical stage biotech company, today announced the expansion of its executive team with the appointment of Scott Hunter as Chief Commercial Officer bringing two decades of eyecare experience across both rare disease and specialty markets.

Inogen, Inc. today announced unaudited preliminary revenue results for the fourth quarter and the full year ended December 31, 2022.

Alto Neuroscience Inc. today reported results from its Phase 2a study of ALTO-100, demonstrating clear evidence of efficacy and favorable safety in patients with MDD.

Arcus Biosciences, Inc. today announced that the Compensation Committee of the Company’s Board of Directors granted one new employee options to purchase a total of 1,450 shares of the Company’s common stock at an exercise price per share of $17.51, which was the closing price on January 9, 2023.

Optimi Health Corp. is pleased to announce that Mr. Bryan Safarik, Mr. Jacob Safarik, Mr. Jon Schintler, Mr. Dane Stevens, and Mr. JJ Wilson have been re-elected to the Board of Directors following the Company’s Annual General Meeting held January 9, 2023.